Overall 2L-4L Kd and Vd group combined baseline patient characteristics by renal response category
| . | RCR (n = 363) . | RPR or RMR (n = 300) . | ROR (n = 663) . | RNR (n = 885) . |
|---|---|---|---|---|
| Age, n (%) | ||||
| <65 y | 110 (30.3) | 62 (20.7) | 172 (25.9) | 188 (21.2) |
| ≥65 y | 253 (69.7) | 238 (79.3) | 491 (74.1) | 697 (78.8) |
| Sex, n (%) | ||||
| Female | 181 (49.9) | 168 (56.0) | 349 (52.6) | 446 (50.4) |
| Male | 182 (50.1) | 132 (44.0) | 314 (47.4) | 439 (49.6) |
| Race, n (%) | ||||
| White | 247 (68.0) | 212 (70.7) | 459 (69.2) | 611 (69.0) |
| African American | 42 (11.6) | 40 (13.3) | 82 (12.4) | 110 (12.4) |
| Asian | 7 (1.9) | 2 (0.7) | 9 (1.4) | 10 (1.1) |
| Hispanic | 5 (1.4) | 1 (0.3) | 6 (0.9) | 2 (0.2) |
| Other | 33 (9.1) | 24 (8.0) | 57 (8.6) | 72 (8.1) |
| Missing | 29 (8.0) | 21 (7.0) | 50 (7.5) | 80 (9.0) |
| ECOG PS, n (%) | ||||
| 0-1 | 141 (38.8) | 117 (39.0) | 258 (38.9) | 378 (42.7) |
| ≥2 | 40 (11.0) | 63 (21.0) | 103 (15.5) | 112 (12.7) |
| Missing | 182 (50.1) | 120 (40.0) | 302 (45.6) | 395 (44.6) |
| eGFR values, n (%), mL/min per 1.73 m2 | ||||
| 45-59 | 179 (49.3) | 5 (1.7) | 184 (27.8) | 232 (26.2) |
| 30-44 | 162 (44.6) | 94 (31.3) | 256 (38.6) | 433 (48.9) |
| 15-29 | 20 (5.5) | 151 (50.3) | 171 (25.8) | 151 (17.1) |
| <15 | 2 (0.6) | 50 (16.7) | 52 (7.8) | 69 (7.8) |
| ISS stage, n (%) | ||||
| I | 82 (22.6) | 9 (3.0) | 91 (13.7) | 106 (12.0) |
| II | 80 (22.0) | 49 (16.3) | 129 (19.5) | 142 (16.0) |
| III | 48 (13.2) | 89 (29.7) | 137 (20.7) | 190 (21.5) |
| Missing | 153 (42.1) | 153 (51.0) | 306 (46.2) | 447 (50.5) |
| Most common 1L treatment regimens, n (%) | ||||
| Most common | BTZ+DEX, 127 (35.0) | BTZ+DEX, 122 (40.7) | BTZ+DEX, 249 (37.6) | BTZ+DEX, 365 (41.2) |
| Second most common | LEN+DEX, 80 (22.0) | LEN+DEX, 46 (15.3) | LEN+DEX, 126 (19.0) | LEN+DEX,148 (16.7) |
| Third most common | BTZ+LEN+DEX, 55 (15.2) | BTZ+CP+DEX, 41 (13.7) | BTZ+LEN+DEX, 88 (13.3) | BTZ+CP+DEX, 120 (13.6) |
| Other regimen | 101 (27.8) | 91 (30.3) | 200 (30.2) | 252 (28.5) |
| Median time from diagnosis to 2L initiation, months (IQR) | 17.2 (8-35) | 15.7 (9-29) | 16.6 (9-32) | 16.5 (9-33) |
| Serum calcium, mean mg/dL, (SD) | 9.2 (0.8) | 9.1 (0.8) | 9.2 (0.8) | 9.2 (0.7) |
| Serum free light-chain ratio, mean (SD) | 142.3 (737) | 162.7 (770.3) | 151.1 (750.3) | 105.0 (443.1) |
| Serum LDH, mean U/L, (SD) | 233.6 (149.5) | 248.9 (161.1) | 239.9 (154.2) | 215.5 (114.3) |
| Whole blood hemoglobin, mean g/dL, (SD) | 10.9 (1.7) | 10.3 (1.5) | 10.6 (1.7) | 10.8 (1.7) |
| . | RCR (n = 363) . | RPR or RMR (n = 300) . | ROR (n = 663) . | RNR (n = 885) . |
|---|---|---|---|---|
| Age, n (%) | ||||
| <65 y | 110 (30.3) | 62 (20.7) | 172 (25.9) | 188 (21.2) |
| ≥65 y | 253 (69.7) | 238 (79.3) | 491 (74.1) | 697 (78.8) |
| Sex, n (%) | ||||
| Female | 181 (49.9) | 168 (56.0) | 349 (52.6) | 446 (50.4) |
| Male | 182 (50.1) | 132 (44.0) | 314 (47.4) | 439 (49.6) |
| Race, n (%) | ||||
| White | 247 (68.0) | 212 (70.7) | 459 (69.2) | 611 (69.0) |
| African American | 42 (11.6) | 40 (13.3) | 82 (12.4) | 110 (12.4) |
| Asian | 7 (1.9) | 2 (0.7) | 9 (1.4) | 10 (1.1) |
| Hispanic | 5 (1.4) | 1 (0.3) | 6 (0.9) | 2 (0.2) |
| Other | 33 (9.1) | 24 (8.0) | 57 (8.6) | 72 (8.1) |
| Missing | 29 (8.0) | 21 (7.0) | 50 (7.5) | 80 (9.0) |
| ECOG PS, n (%) | ||||
| 0-1 | 141 (38.8) | 117 (39.0) | 258 (38.9) | 378 (42.7) |
| ≥2 | 40 (11.0) | 63 (21.0) | 103 (15.5) | 112 (12.7) |
| Missing | 182 (50.1) | 120 (40.0) | 302 (45.6) | 395 (44.6) |
| eGFR values, n (%), mL/min per 1.73 m2 | ||||
| 45-59 | 179 (49.3) | 5 (1.7) | 184 (27.8) | 232 (26.2) |
| 30-44 | 162 (44.6) | 94 (31.3) | 256 (38.6) | 433 (48.9) |
| 15-29 | 20 (5.5) | 151 (50.3) | 171 (25.8) | 151 (17.1) |
| <15 | 2 (0.6) | 50 (16.7) | 52 (7.8) | 69 (7.8) |
| ISS stage, n (%) | ||||
| I | 82 (22.6) | 9 (3.0) | 91 (13.7) | 106 (12.0) |
| II | 80 (22.0) | 49 (16.3) | 129 (19.5) | 142 (16.0) |
| III | 48 (13.2) | 89 (29.7) | 137 (20.7) | 190 (21.5) |
| Missing | 153 (42.1) | 153 (51.0) | 306 (46.2) | 447 (50.5) |
| Most common 1L treatment regimens, n (%) | ||||
| Most common | BTZ+DEX, 127 (35.0) | BTZ+DEX, 122 (40.7) | BTZ+DEX, 249 (37.6) | BTZ+DEX, 365 (41.2) |
| Second most common | LEN+DEX, 80 (22.0) | LEN+DEX, 46 (15.3) | LEN+DEX, 126 (19.0) | LEN+DEX,148 (16.7) |
| Third most common | BTZ+LEN+DEX, 55 (15.2) | BTZ+CP+DEX, 41 (13.7) | BTZ+LEN+DEX, 88 (13.3) | BTZ+CP+DEX, 120 (13.6) |
| Other regimen | 101 (27.8) | 91 (30.3) | 200 (30.2) | 252 (28.5) |
| Median time from diagnosis to 2L initiation, months (IQR) | 17.2 (8-35) | 15.7 (9-29) | 16.6 (9-32) | 16.5 (9-33) |
| Serum calcium, mean mg/dL, (SD) | 9.2 (0.8) | 9.1 (0.8) | 9.2 (0.8) | 9.2 (0.7) |
| Serum free light-chain ratio, mean (SD) | 142.3 (737) | 162.7 (770.3) | 151.1 (750.3) | 105.0 (443.1) |
| Serum LDH, mean U/L, (SD) | 233.6 (149.5) | 248.9 (161.1) | 239.9 (154.2) | 215.5 (114.3) |
| Whole blood hemoglobin, mean g/dL, (SD) | 10.9 (1.7) | 10.3 (1.5) | 10.6 (1.7) | 10.8 (1.7) |
BTZ, bortezomib; CP, cyclophosphamide; DEX, dexamethasone; EOT, end of treatment; LEN, lenalidomide; SD, standard deviation.